Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

Long-term follow-up of a combined rituximab and cyclophosphamide regimen in renal anti-neutrophil cytoplasm antibody-associated vasculitis.

McAdoo SP, Medjeral-Thomas N, Gopaluni S, Tanna A, Mansfield N, Galliford J, Griffith M, Levy J, Cairns TD, Jayne D, Salama AD, Pusey CD.

Nephrol Dial Transplant. 2018 May 1;33(5):899. doi: 10.1093/ndt/gfy075. No abstract available.

PMID:
29617842
2.

Ofatumumab for B cell depletion in patients with systemic lupus erythematosus who are allergic to rituximab.

Masoud S, McAdoo SP, Bedi R, Cairns TD, Lightstone L.

Rheumatology (Oxford). 2018 Mar 19. doi: 10.1093/rheumatology/key042. [Epub ahead of print]

PMID:
29562252
3.

Long-term follow-up of a combined rituximab and cyclophosphamide regimen in renal anti-neutrophil cytoplasm antibody-associated vasculitis.

McAdoo SP, Medjeral-Thomas N, Gopaluni S, Tanna A, Mansfield N, Galliford J, Griffith M, Levy J, Cairns TD, Jayne D, Salama AD, Pusey CD.

Nephrol Dial Transplant. 2018 Feb 14. doi: 10.1093/ndt/gfx378. [Epub ahead of print]

4.

Predicting Outcome in Patients with Anti-GBM Glomerulonephritis.

van Daalen EE, Jennette JC, McAdoo SP, Pusey CD, Alba MA, Poulton CJ, Wolterbeek R, Nguyen TQ, Goldschmeding R, Alchi B, Griffiths M, de Zoysa JR, Vincent B, Bruijn JA, Bajema IM.

Clin J Am Soc Nephrol. 2018 Jan 6;13(1):63-72. doi: 10.2215/CJN.04290417. Epub 2017 Nov 21.

PMID:
29162595
5.

BCAT1 controls metabolic reprogramming in activated human macrophages and is associated with inflammatory diseases.

Papathanassiu AE, Ko JH, Imprialou M, Bagnati M, Srivastava PK, Vu HA, Cucchi D, McAdoo SP, Ananieva EA, Mauro C, Behmoaras J.

Nat Commun. 2017 Jul 12;8:16040. doi: 10.1038/ncomms16040.

6.

Anti-Glomerular Basement Membrane Disease.

McAdoo SP, Pusey CD.

Clin J Am Soc Nephrol. 2017 Jul 7;12(7):1162-1172. doi: 10.2215/CJN.01380217. Epub 2017 May 17. Review.

7.

Patients double-seropositive for ANCA and anti-GBM antibodies have varied renal survival, frequency of relapse, and outcomes compared to single-seropositive patients.

McAdoo SP, Tanna A, Hrušková Z, Holm L, Weiner M, Arulkumaran N, Kang A, Satrapová V, Levy J, Ohlsson S, Tesar V, Segelmark M, Pusey CD.

Kidney Int. 2017 Sep;92(3):693-702. doi: 10.1016/j.kint.2017.03.014. Epub 2017 May 12.

8.

Is there a role for TNFα blockade in ANCA-associated vasculitis and glomerulonephritis?

McAdoo SP, Pusey CD.

Nephrol Dial Transplant. 2017 Jan 1;32(suppl_1):i80-i88. doi: 10.1093/ndt/gfw361. Review.

9.

Targeting the tyrosine kinase signalling pathways for treatment of immune-mediated glomerulonephritis: from bench to bedside and beyond.

Ma TK, McAdoo SP, Tam FW.

Nephrol Dial Transplant. 2017 Jan 1;32(suppl_1):i129-i138. doi: 10.1093/ndt/gfw336. Review.

10.

Spleen Tyrosine Kinase: A Crucial Player and Potential Therapeutic Target in Renal Disease.

Ma TK, McAdoo SP, Tam FW.

Nephron. 2016;133(4):261-9. doi: 10.1159/000446879. Epub 2016 Jul 30. Review.

11.

Clustering of Anti-GBM Disease: Clues to an Environmental Trigger?

McAdoo SP, Pusey CD.

Clin J Am Soc Nephrol. 2016 Aug 8;11(8):1324-6. doi: 10.2215/CJN.05580516. Epub 2016 Jul 11. No abstract available.

12.

Enhancing Adolescent Reproductive Health Services: Assessment of Health Care Practices in Holyoke and Springfield, MA Engaged in the Youth First Initiative.

Bhuiya NS, Crowley J, Fletcher E, McAdoo SP, Middleton D, Hallum-Montes R, Waggett J, Tendulkar SA.

J Health Care Poor Underserved. 2016;27(2):495-509. doi: 10.1353/hpu.2016.0062.

PMID:
27180691
13.

Ofatumumab for B cell depletion therapy in ANCA-associated vasculitis: a single-centre case series.

McAdoo SP, Bedi R, Tarzi R, Griffith M, Pusey CD, Cairns TD.

Rheumatology (Oxford). 2016 Aug;55(8):1437-42. doi: 10.1093/rheumatology/kew199. Epub 2016 Apr 19.

14.

Renal tubular disease in the era of combination antiretroviral therapy.

Hamzah L, Booth JW, Jose S, McAdoo SP, Kumar EA, O'Donnell P, Hilton R, Sabin C, Williams DI, Jones R, Post FA; HIVCKD Study.

AIDS. 2015 Sep 10;29(14):1831-6. doi: 10.1097/QAD.0000000000000736.

PMID:
26372389
15.

Long-term Outcomes of Rituximab Therapy in Ocular Granulomatosis with Polyangiitis: Impact on Localized and Nonlocalized Disease.

Joshi L, Tanna A, McAdoo SP, Medjeral-Thomas N, Taylor SR, Sandhu G, Tarzi RM, Pusey CD, Lightman S.

Ophthalmology. 2015 Jun;122(6):1262-8. doi: 10.1016/j.ophtha.2015.01.016. Epub 2015 Mar 4.

PMID:
25745876
16.

Correlation of disease activity in proliferative glomerulonephritis with glomerular spleen tyrosine kinase expression.

McAdoo SP, Bhangal G, Page T, Cook HT, Pusey CD, Tam FW.

Kidney Int. 2015 Jul;88(1):52-60. doi: 10.1038/ki.2015.29. Epub 2015 Feb 25.

17.

Immunodeficiency-associated renal Burkitt lymphoma.

White W, Blunden M, McAdoo SP, Sheaff M, Hallam S, McCafferty K.

Br J Haematol. 2015 Mar;168(6):769. doi: 10.1111/bjh.13246. Epub 2014 Nov 29. No abstract available.

PMID:
25441761
18.

Necrotizing and crescentic glomerulonephritis presenting with preserved renal function in patients with underlying multisystem autoimmune disease: a retrospective case series.

McAdoo SP, Tanna A, Randone O, Tam FW, Tarzi RM, Levy JB, Griffith M, Lightstone L, Cook HT, Cairns T, Pusey CD.

Rheumatology (Oxford). 2015 Jun;54(6):1025-32. doi: 10.1093/rheumatology/keu445. Epub 2014 Nov 26.

19.

Spleen tyrosine kinase inhibition attenuates autoantibody production and reverses experimental autoimmune GN.

McAdoo SP, Reynolds J, Bhangal G, Smith J, McDaid JP, Tanna A, Jackson WD, Masuda ES, Cook HT, Pusey CD, Tam FW.

J Am Soc Nephrol. 2014 Oct;25(10):2291-302. doi: 10.1681/ASN.2013090978. Epub 2014 Apr 3.

20.

Should rituximab be used to prevent relapse in patients with ANCA-associated vasculitis?

McAdoo SP, Pusey CD.

Clin J Am Soc Nephrol. 2014 Apr;9(4):641-4. doi: 10.2215/CJN.01270214. Epub 2014 Mar 13. No abstract available.

21.

Experimental crescentic glomerulonephritis: a new bicongenic rat model.

D'Souza Z, McAdoo SP, Smith J, Pusey CD, Cook HT, Behmoaras J, Aitman TJ.

Dis Model Mech. 2013 Nov;6(6):1477-86. doi: 10.1242/dmm.012328. Epub 2013 Aug 15.

22.

L46. Novel forms of clinical vasculitis: anti-GBM vasculitis (Goodpasture's disease).

McAdoo SP, Pusey CD.

Presse Med. 2013 Apr;42(4 Pt 2):625-8. doi: 10.1016/j.lpm.2013.01.043. Epub 2013 Mar 9. Review. No abstract available.

PMID:
23477716
23.

Proteinase-3 antineutrophil cytoplasm antibody positivity in patients without primary systemic vasculitis.

McAdoo SP, Hall A, Levy J, Salama AD, Pusey CD.

J Clin Rheumatol. 2012 Oct;18(7):336-40. doi: 10.1097/RHU.0b013e31826d2005.

PMID:
23047533
24.
25.

Acute renal failure in diabetes: looking beyond diabetic retinopathy.

McAdoo SP, Pusey CD.

Clin Med (Lond). 2011 Dec;11(6):629; author reply 629-30. No abstract available.

PMID:
22268330
26.

Measuring the quality of end of life management in patients with advanced kidney disease: results from the pan-Thames renal audit group.

McAdoo SP, Brown EA, Chesser AM, Farrington K, Salisbury EM; pan-Thames renal audit group.

Nephrol Dial Transplant. 2012 Apr;27(4):1548-54. doi: 10.1093/ndt/gfr514. Epub 2011 Oct 6.

PMID:
21980155
27.

Bacterial endocarditis associated with proteinase 3 anti-neutrophil cytoplasm antibody.

McAdoo SP, Densem C, Salama A, Pusey CD.

NDT Plus. 2011 Jun;4(3):208-210. No abstract available.

28.

Fostamatinib Disodium.

McAdoo SP, Tam FW.

Drugs Future. 2011;36(4):273.

Supplemental Content

Loading ...
Support Center